scholarly journals C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: Defining subtypes of nonresponse and subsequent response to etanercept

2005 ◽  
Vol 52 (1) ◽  
pp. 42-48 ◽  
Author(s):  
Maya H. Buch ◽  
Yohei Seto ◽  
Sarah J. Bingham ◽  
Victoria Bejarano ◽  
Domini Bryer ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Treatment Outcome ◽  
Infliximab Treatment ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Subsequent Response

scholarly journals The Clinical Application of Anti-CCP in Rheumatoid Arthritis and Other Rheumatic Diseases

2007 ◽  
Vol 2 ◽  
pp. 117727190700200 ◽  
Author(s):  
CT Chou ◽  
HT Liao ◽  
CH Chen ◽  
WS Chen ◽  
HP Wang ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Treatment Outcome ◽  
Laboratory Test ◽  
Clinical Features ◽  
Rheumatic Diseases ◽  
Clinical Symptoms ◽  
High Specificity ◽  
C Reactive Protein ◽  
Clinical Criteria ◽  
Reactive Protein

Rheumatoid arthritis (RA) is a common rheumatic disease in Caucasians and in other ethnic groups. Diagnosis is mainly based on clinical features. Before 1998, the only serological laboratory test that could contribute to the diagnosis was that for rheumatoid factor (RF). The disease activity markers for the evaluation of clinical symptoms or treatment outcome were the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). As a matter of fact, the diagnosis of early RA is quite impossible, as the clinical criteria are insufficient at the beginning stage of the disease. In 1998, Schelleken reported that a high percentage of RA patients had a specific antibody that could interact with a synthetic peptide which contained the amino acid citrulline. The high specificity (98%) for RA of this new serological marker, anti-cyclic citrullinated antibody (anti-CCP antibody), can be detected early in RA, before the typical clinical features appear. The presence or absence of this antibody can easily distinguish other rheumatic diseases from RA. Additionally, the titer of anti-CCP can be used to predict the prognosis and treatment outcome after DMARDs or biological therapy. Therefore, with improvement of sensitivity, the anti-CCP antibody will be widely used as a routine laboratory test in the clinical practice for RA.

Role of high sensitivity C - Reactive protein and some of heavy metals in patients with rheumatoid arthritis

2020 ◽  
Vol 23 (16) ◽  
Author(s):  
Nashwan S. Albabawaty ◽  
Ali Y. Majid ◽  
Mohammed H. Alosami ◽  
Halla G. Mahmood
Keyword(s):  
Rheumatoid Arthritis ◽  
Heavy Metals ◽  
High Sensitivity ◽  
C Reactive Protein ◽  
Reactive Protein

Anti-TNF-α Treatment Reduces the Baseline Procoagulant Imbalance of Patients With Inflammatory Bowel Diseases

2021 ◽  
Author(s):  
Armando Tripodi ◽  
Luisa Spina ◽  
Laura Francesca Pisani ◽  
Lidia Padovan ◽  
Flaminia Cavallaro ◽  
...  
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Coagulation Factors ◽  
Infliximab Treatment ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Thrombosis Risk ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Factor Α

Abstract Background Inflammatory bowel diseases (IBD) are characterized by an increased thrombosis risk of uncertain etiology. Coagulation derangement arising from inflammation may be a triggering factor. We hypothesized that strong inflammation inhibitors (eg, anti-tumor necrosis factor-α drugs) may affect coagulation. Methods Forty patients with IBD were compared with 57 control patients for coagulation factors and endogenous thrombin potential (ETP), the latter being the most sensitive marker of in vivo pro- and anticoagulation balance. We measured ETP in the presence and absence of thrombomodulin (the physiologic protein C [PC] activator). Coagulation at different timepoints was also assessed for 28 of these patients during infliximab treatment. Results The median ETP (nM thrombin × minutes) and range (minimum-maximum) were each higher in patients at baseline than in control patients in both the absence (2120 [1611-3041] vs 1865 [1270-2337]) and the presence (1453 [464-2522] vs 831 [104-1741]) of thrombomodulin. The ETP ratio (with/without thrombomodulin) was high at baseline (0.73 [0.21-0.90] vs 0.45 [0.07-0.85]). The ETP and ETP ratio declined during treatment and were significantly lower at the end than at baseline. Factor (F) VIII and fibrinogen, which were high at baseline, decreased during treatment and at the end were significantly lower than at baseline. The FVIII/PC ratio, which was high in patients at baseline, declined during treatment and at the end was lower than at baseline. C-reactive protein recorded at the end of treatment was lower than at baseline. Conclusions Patients with IBD have a procoagulant imbalance as shown by increased ETP at baseline. The ETP decreases during treatment with infliximab, which is related to decreased FVIII and FVIII/PC ratio. This effect is also related to the improvement of inflammation as shown by decreased fibrinogen and C-reactive protein.

A comparison of postoperative C-reactive protein changes in primary and revision hip arthroplasty in patients with rheumatoid arthritis

2002 ◽  
Vol 17 (1) ◽  
pp. 108-110 ◽  
Author(s):  
Heikki M[auml ]enp[auml ][auml ] ◽  
Kari Laiho ◽  
Markku Kauppi ◽  
Kalevi Kaarela ◽  
Hannu Kautiainen ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Hip Arthroplasty ◽  
Revision Hip Arthroplasty ◽  
C Reactive Protein ◽  
Reactive Protein

scholarly journals Serum Levels of Anticyclic Citrullinated Peptide Antibodies, Interleukin-6, Tumor Necrosis Factor-α, and C-Reactive Protein Are Associated with Increased Carotid Intima-Media Thickness: A Cross-Sectional Analysis of a Cohort of Rheumatoid Arthritis Patients without Cardiovascular Risk Factors

2015 ◽  
Vol 2015 ◽  
pp. 1-10 ◽  
Author(s):  
Mónica Vázquez-Del Mercado ◽  
Lourdes Nuñez-Atahualpa ◽  
Mauricio Figueroa-Sánchez ◽  
Eduardo Gómez-Bañuelos ◽  
Alberto Daniel Rocha-Muñoz ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Cardiovascular Risk ◽  
Cardiovascular Events ◽  
Tumor Necrosis ◽  
Intima Media Thickness ◽  
Carotid Intima Media Thickness ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Citrullinated Peptide ◽  
Necrosis Factor

The main cause of death in rheumatoid arthritis (RA) is cardiovascular events. We evaluated the relationship of anticyclic citrullinated peptide (anti-CCP) antibody levels with increased carotid intima-media thickness (cIMT) in RA patients.Methods. Forty-five anti-CCP positive and 37 anti-CCP negative RA patients, and 62 healthy controls (HC) were studied. All groups were assessed for atherogenic index of plasma (AIP) and cIMT. Anti-CCP, C-reactive protein (CRP), and levels of tumor necrosis factor alpha (TNFα) and interleukin-6 (IL-6) were measured by enzyme-linked immunosorbent assay (ELISA).Results. The anti-CCP positive RA patients showed increased cIMT compared to HC and anti-CCP negative (P<0.001). Anti-CCP positive versus anti-CCP negative RA patients, had increased AIP, TNFαand IL-6 (P<0.01), and lower levels of high density lipoprotein cholesterol (HDL-c) (P=0.02). The cIMT correlated with levels of anti-CCP (r=0.513,P=0.001), CRP (r=0.799,P<0.001), TNFα(r=0.642,P=0.001), and IL-6 (r=0.751,P<0.001). In multiple regression analysis, cIMT was associated with CRP (P<0.001) and anti-CCP levels (P=0.03).Conclusions. Levels of anti-CCP and CRP are associated with increased cIMT and cardiovascular risk supporting a clinical role of the measurement of cIMT in RA in predicting and preventing cardiovascular events.

Sign in / Sign up

Export Citation Format

Share Document